• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.

作者信息

Hahn Andrew W, Aparicio Ana, Jadvar Hossein, Poon Darren M C

机构信息

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

出版信息

Prostate Cancer Prostatic Dis. 2024 Nov 18. doi: 10.1038/s41391-024-00922-z.

DOI:10.1038/s41391-024-00922-z
PMID:39558122
Abstract
摘要

相似文献

1
MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.多学科团队视角：立体定向体部放射治疗在转移性去势抵抗性前列腺癌中的创新应用
Prostate Cancer Prostatic Dis. 2024 Nov 18. doi: 10.1038/s41391-024-00922-z.
2
Stereotactic ablative radiation therapy in metastatic prostate cancer.立体定向消融放疗治疗转移性前列腺癌。
Curr Opin Oncol. 2024 May 1;36(3):180-185. doi: 10.1097/CCO.0000000000001025. Epub 2024 Feb 15.
3
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.阿比特龙/恩杂鲁胺治疗期间，对转移性去势抵抗性前列腺癌患者的寡进展性病灶进行立体定向体部放疗。
Prostate. 2021 Jun;81(9):543-552. doi: 10.1002/pros.24132. Epub 2021 Apr 27.
4
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.镭-223与立体定向消融放疗对比立体定向消融放疗治疗寡转移前列腺癌的疗效：RAVENS II期随机试验
J Clin Oncol. 2025 Jun 20;43(18):2059-2068. doi: 10.1200/JCO-25-00131. Epub 2025 May 7.
5
The efficacy of metastasis-directed external beam radiotherapy for castration-resistant prostate cancer: A retrospective multicenter study.转移性去势抵抗性前列腺癌的外照射放疗疗效：一项回顾性多中心研究。
Curr Urol. 2025 Sep;19(5):314-320. doi: 10.1097/CU9.0000000000000293. Epub 2025 Jul 16.
6
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
7
Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.寡进展性转移性去势抵抗性前列腺癌在阿比特龙或恩杂鲁胺治疗期间行立体定向体部放疗。
Tumori. 2023 Aug;109(4):413-417. doi: 10.1177/03008916221132592. Epub 2022 Nov 10.
8
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.转移灶定向治疗延长寡进展性去势抵抗性前列腺癌系统治疗的疗效并改善临床结局。
Eur Urol Oncol. 2021 Jun;4(3):447-455. doi: 10.1016/j.euo.2020.05.004. Epub 2020 Jun 11.
9
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌的立体定向体部放射治疗现状
Prostate Cancer Prostatic Dis. 2024 Jun 19. doi: 10.1038/s41391-024-00862-8.
10
Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.寡转移前列腺癌根治术后转移导向治疗后复发的预测因素。
Eur Urol Oncol. 2023 Dec;6(6):582-589. doi: 10.1016/j.euo.2023.02.010. Epub 2023 Mar 4.

引用本文的文献

1
HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.同源重组修复缺陷指导下的他拉唑帕尼联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌患者：成本效益分析
Ther Adv Med Oncol. 2025 Jul 13;17:17588359251356109. doi: 10.1177/17588359251356109. eCollection 2025.
2
Salvage Ultrasound-Guided Robot-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) as a Metastasis-Directed Therapy (MDT) in Oligoprogressive Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case Report and Review of the Literature.挽救性超声引导下机器人辅助视频内镜腹股沟淋巴结清扫术（RAVEIL）作为寡进展性转移性去势抵抗性前列腺癌（mCRPC）的转移导向治疗（MDT）：一例病例报告及文献复习
Curr Oncol. 2025 Feb 18;32(2):115. doi: 10.3390/curroncol32020115.

本文引用的文献

1
Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.前列腺特异性膜抗原 PET/CT 引导下寡转移去势抵抗性前列腺癌转移灶导向放疗
J Nucl Med. 2024 Sep 3;65(9):1387-1394. doi: 10.2967/jnumed.124.267922.
2
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).多种成像方法可能会影响接受转移灶定向治疗的寡转移性前列腺癌患者的长期肿瘤学结局（PRECISE-MDT研究）。
J Nucl Med. 2024 Aug 1;65(8):1202-1209. doi: 10.2967/jnumed.124.267586.
3
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer.
转移性去势抵抗性前列腺癌的立体定向体部放射治疗现状
Prostate Cancer Prostatic Dis. 2024 Jun 19. doi: 10.1038/s41391-024-00862-8.
4
Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial.高风险无症状骨转移患者预防性放疗与标准治疗的比较：一项多中心、随机、Ⅱ期临床试验。
J Clin Oncol. 2024 Jan 1;42(1):38-46. doi: 10.1200/JCO.23.00753. Epub 2023 Sep 25.
5
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).寡转移去势抵抗性前列腺癌患者接受立体定向体部放疗联合醋酸阿比特龙治疗的随机Ⅱ期临床试验（ARTO）
J Clin Oncol. 2023 Dec 20;41(36):5561-5568. doi: 10.1200/JCO.23.00985. Epub 2023 Sep 21.
6
Lesion Dosimetry for [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.[Lu]Lu-PSMA-617 放射性药物治疗联合立体定向体部放射治疗寡转移去势敏感性前列腺癌患者的病灶剂量学
J Nucl Med. 2023 Nov;64(11):1779-1787. doi: 10.2967/jnumed.123.265763. Epub 2023 Aug 31.
7
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.寡转移前列腺癌间歇性激素治疗中加入转移灶定向治疗：EXTEND 期 2 随机临床试验。
JAMA Oncol. 2023 Jun 1;9(6):825-834. doi: 10.1001/jamaoncol.2023.0161.
8
Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET.PSMA PET时代复发性和异时性寡转移性前列腺癌患者的管理
Cancers (Basel). 2022 Dec 15;14(24):6194. doi: 10.3390/cancers14246194.
9
Oligometastatic Prostate Cancer: Current Status and Future Challenges.寡转移前列腺癌：现状与未来挑战。
J Nucl Med. 2022 Nov;63(11):1628-1635. doi: 10.2967/jnumed.121.263124.
10
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus.寡转移前列腺癌放射治疗推荐：ESTRO-ACROP 德尔菲共识。
Radiother Oncol. 2022 Nov;176:199-207. doi: 10.1016/j.radonc.2022.10.005. Epub 2022 Oct 10.